This company is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
AVROBIO Crescita futura
Future criteri di controllo 0/6
AVROBIO's earnings are forecast to decline at 18.4% per annum. EPS is expected to decline by 18% per annum.
Informazioni chiave
-18.4%
Tasso di crescita degli utili
-18.0%
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 28.5% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | 04 Jun 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK
Oct 18Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status
Sep 20AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy
Jul 13Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Nov 13We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
Aug 10AVROBIO: Fabrazyme's Full Approval Changes Things
May 05Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation
Mar 08AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise
Dec 25We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth
Nov 23AVROBIO readies $75M equity offering
Nov 19AVROBIO EPS misses by $0.19
Nov 05Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | N/A | -2 | N/A | N/A | 1 |
12/31/2025 | N/A | -7 | N/A | N/A | 1 |
12/31/2024 | N/A | -21 | N/A | N/A | 1 |
3/31/2024 | N/A | 30 | -50 | -50 | N/A |
12/31/2023 | N/A | 12 | -63 | -63 | N/A |
9/30/2023 | N/A | -4 | -79 | -79 | N/A |
6/30/2023 | N/A | -5 | -75 | -75 | N/A |
3/31/2023 | N/A | -101 | -90 | -89 | N/A |
12/31/2022 | N/A | -106 | -97 | -97 | N/A |
9/30/2022 | N/A | -109 | -101 | -99 | N/A |
6/30/2022 | N/A | -119 | -109 | -108 | N/A |
3/31/2022 | N/A | -122 | -101 | -99 | N/A |
12/31/2021 | N/A | -119 | -100 | -98 | N/A |
9/30/2021 | N/A | -119 | -104 | -103 | N/A |
6/30/2021 | N/A | -123 | -104 | -103 | N/A |
3/31/2021 | N/A | -121 | -104 | -104 | N/A |
12/31/2020 | N/A | -120 | -100 | -99 | N/A |
9/30/2020 | N/A | -114 | -89 | -87 | N/A |
6/30/2020 | N/A | -95 | -77 | -75 | N/A |
3/31/2020 | N/A | -82 | -74 | -72 | N/A |
12/31/2019 | N/A | -73 | -69 | -68 | N/A |
9/30/2019 | N/A | -66 | -62 | -61 | N/A |
6/30/2019 | N/A | -61 | -61 | -59 | N/A |
3/31/2019 | N/A | -55 | -51 | -49 | N/A |
12/31/2018 | N/A | -49 | -39 | -38 | N/A |
9/30/2018 | N/A | -40 | -36 | -35 | N/A |
6/30/2018 | N/A | -35 | -27 | -26 | N/A |
3/31/2018 | N/A | -27 | -21 | -20 | N/A |
12/31/2017 | N/A | -19 | N/A | -16 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: AVRO's earnings are forecast to decline over the next 3 years (-18.4% per year).
Guadagni vs Mercato: AVRO's earnings are forecast to decline over the next 3 years (-18.4% per year).
Guadagni ad alta crescita: AVRO's earnings are forecast to decline over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if AVRO's revenue is forecast to grow faster than the US market.
Ricavi ad alta crescita: AVRO is forecast to have no revenue next year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if AVRO's Return on Equity is forecast to be high in 3 years time